In the previous papers' 2), we have first reported that the 1-N-acyl-3"-N-trifluoroacetylkanamycin A derivatives had the strong antiviral activity against herpes simplex virus type I (HSV-I) and influenza virus, and have described the structure-activity relationships between the antiviral activity and alkyl chain length in an acyl group at the N-I position. 3"-N-Trifluoroacetylkanamycin A derivatives having a higher-acyl group, such as palmitoyl, pentadecanoyl, or hexadecanyloxycarbonyl, were found to have excellent antiviral activity against both HSV-I (ID,, 1.0-'1.4 pg/ml) and influenza virus (ID, 5.6-' 22 pg/ml). We have also suggested that the introduction of a higher-acyl group in the kanamycin A molecule was essential for strong antiviral activity. While, 1-N-higher-acyl-3"-N-trifluoroacetylkanamycin A derivatives') exhibited excellent antiviral activity. They were very soluble in water under acidic condition (pH<5.8), but were slightly soluble in water (0.1 mg/ml) at around neutral pH. Based on these facts, we felt that the I-N-higher-acylkanamycin A derivatives bearing various acyl groups in place of the trifluoroacetyl radical at the N-3" position might improve the activity over that of 1-N-palmitoyl-3"-N-trifluoroacetylkanamycin A (7u). Furthermore, the 1-Nhigher-acylkanamycin A derivatives having a functionalized acyl group, such as amino group and/or hydroxyl group, at the N-3" position could be soluble in water at neutral pH.
In this paper, we report the synthesis and antiviral activity of the 1-N-higher-acylkanamycin A derivatives (7, 8, 9) having a variety of acyl group at the N-3" position.
Chemistry
We synthesized 1-N-higher-acyl-3"-N-functionalized acylkanamycin A derivatives (7, 8, 9) as follows (Schemes 1 and 2).
Protection of two amino groups at the C-3 and C-6' positions of kanamycin A (1) by reaction with N-benzyloxycarbonyloxy-5-norbomene-2,3-dicarboximide, followed by regiospecific 3"-amino protection with ethyl trifluoroacetate, gave 3,6'-bis-N-benzyloxycarbonyl-3"-N-trifluoroacetylkanamycin A (2) by using the method of TsuCHIYA et a1.3). Acylation of 2 with an acyl chloride or an activated ester gave the corresponding 1-N-acyl-3,6'-bis(N-benzyloxycarbonyl)-3"-N-trifluoroacetylkanamycin A derivatives (3) as reported in the previous paper'). Physical data and yields of 3 are summarized in Table 1 . Removal of the trifluoroacetyl group of 3 under alkaline condition (1 M NH,OH -aqueous THE or KOH -MeOH) was unsuccessful, because steric hindrance of the higher-acyl group at the N-1 position might prevent hydroxide anion from attacking the trifluoroacetyl group at the N-3"
position. Therefore, we assumed that acetylation of the hydroxyl groups in 3 could overcome this steric hindrance by changing the conformation of 3. Acetylation of 3 with acetic anhydride gave the corresponding 2',3',4',2",4",6"-hexa-O-acetyl-l-N-acyl-3,6'-bis(N-benzyloxycarbonyl)-3"-N-trifluoroacetylkanamycin A derivatives (4), ( Table 2) . Treatment of 4 with a solution of KOH in methanol afforded the 1-N-acyl-3,6'-bis(N-benzyloxycarbonyl)kanamycin A derivatives (5) in good yield (Table   3 ). Acylation of 5 with an acyl chloride or an activated ester gave the 1-N-acyl-3,6'-bis(N-benzyloxycarbonyl)-3"-N-acylkanamycin A derivatives (6) as a solid (Tables 4, 5 and 6 ). Finally, hydrogenation of 6 with 10% palladium on carbon, followed by Iyophilization afforded the corresponding 1-N-acyl-3"-N-functionalized acylkanamycin A di-or trihydrochloride (7, 8, 9) as a hygroscopic solid (Tables  7, 8 and 9) .
On the other hand, reaction of 2 with 2-(tert-butoxycarbonyloximino)-2-phenylacetonitrile in Table 2 . Physical data and yields of 2',3',4',2",4",6"-hexa-O-acetyl-l-N-acyl-3,6'-bis(N-benzyloxycarbonyl)-3"-N-trifluoroacetylkanamycin A derivatives (4) . Table 10 . Antiviral Activity against HSV-I:
The 3"-N-unsubstituted (7a), 3"-N-formyl (7b), 3"-N-acetyl analogs (7c) having palmitoyl group at the N-1 position exhibited excellent antiviral activity against HSV-I (ID,, 1.0' 3.2 ug/ml) and were about 30 times more active than virazole4), though they were 20 times less active than acyclovir".
The 1-N-palmitoyl analogs (7d, e, f) having propionyl, butyryl, or iso-butyryl group at the N-3" position also showed remarkable antiviral activity against HSV-I (ID, 1.74.8 ,ug/ml). Further, the analogs (7g, h, i) having a bulky acyl group, such as tert-butylacetyl, benzoyl, or adamantylacetyl group, exhibited remarkable activity against HSV-I (ID,, 2.7 ' 3.2 ,ug/ml). The 3"-N-chloroacetyl analog (7j) showed similar activity against HSV-I to the 3"-N-trifluoroacetyl analog (7u). However, the analogs (7k, 1, m) having an acyl group with hydroxyl radical, such as hydroxyacetyl, 2-hydroxypropionyl, or 3-hydroxybutyryl group were about 2 times less active (ID,, 2.7-7.8 jug/ml) than 7u. The 3"-N-glycyl analog (7o) exhibited the strongest antiviral activity against HSV-I (ID,O 1.0 yg/ml) in this series and was 30 times more active than virazole, but was 30 times less active than acyclovir. Furthermore, the 3"-N-carbamoyl (7n), 3"-N-((S)-3-amino-2-hydroxypropionyl) (7p), and 3"-N-(S)-(2,4-diaminobutyryl) (7q) analogs were about 3 times less active than 7u.
The cytotoxicity of these 3"-N-acyl derivatives (7) tended to increase as compared with that of 3"-N-trifluoroacetyl derivative (7u). exhibited remarkable antiviral activity against influenza virus (ID,, 10-32 ,ug/ml) and showed similar activity to 7u. However, analogs (7f, h, i) having a bulky acyl group at the N-3" position tended to decrease antiviral activity against influenza virus. Further, analogs (7k-q) having an acyl group with functional groups (hydroxyl and/or amino group(s)) at the N-3" position exhibited much less antiviral activity against influenza virus, and their activity was about 6 times less than that of amantadine0'. Table 6 . Physical data and yields of 1- Table 11 .
Antiviral Activity against HSV-I:
The 3"-N-unsubstituted derivative (8a) having 3-hydroxytetradecanoyl group at the N-I position exhibited excellent antiviral activity against HSV-I (ID,0 1.7 pg/ml). The activity of 8a was 4 times more than that of the 3"-N-trifluoroacetyl analog (8d) and was similar to that of the 1-N-palmitoyl-3"-N-trifluoroacetylkanamycin A (7u). The 3"-N-glycyl analog (8e) showed remarkable antiviral activity (ID, 3.8 ug/ml) and was 2 times less active than 7u. However, analogs (8b, c, f) having formyl, The analogs (8a-f) described above exhibited little or no antiviral activity against influenza virus in contrast with antiviral activity against HSV-I.
The cytotoxicity of 8 was more than 100 fig/ml similarly to that of 7u.
Effect of Higher-acyl Group at the N-1 Position of 3"-N-Glycylkanamycin A
The antiviral activity and cytotoxicity of the 3"-N-glycylkanamycin A derivatives (9) having a higher acyl group at the N-1 position are summarized in Table 12 . derivatives also showed excellent antiviral activity against HSV-I (ID,,, 1.1 2.7 iig/ml). However, the 1-N-(3-hydroxydecanoyl) derivative (9d) exhibited no antiviral activity.
The cytotoxicity of these derivatives (9) was slightly stronger than that of 7u.
Antiviral Activity against Influenza Virus:
The 1-N-pentadecanoyl derivative (9a) having glycyl group at the N-3" position exhibited strong antiviral activity against influenza virus (ID,,, 5 i'g/ml). The derivative (9a) was 2 times more active than amantadine and virazole and was 3 times more active than the 1-N-palmitoyl-3"-N-trifluoroacetylkanamycin A (7u). The 3"-N-glycylkanamycin A derivatives (9e, f) having 3-hydroxyhexadecanoyl or 3-hydroxyoctadecanoyl group at the N-1 position showed similar antiviral activity against influenza virus to the derivative (7u).
Discussion
In this series, the 1-N-palmitoyl-3"-N-unsubstituted (7a) and I-N pentadecanoyl-3"-N-glycyl (9a) derivatives exhibited excellent antiviral activity against not only HSV-I but also influenza virus, and were also soluble in water (>0.1 mg/ml) at around neutral pH. Further, the derivatives (7g--i) having a bulky acyl group at the hN-3" position showed remarkable antiviral activity against HSV-I, but tended to decrease antiviral activity against influenza virus. On the basis of these results, the acyl group at the N-3" position was not essential to give rise to the strong antiviral activity. The balance between lipophilic and hydrophilic character in the kanamycin A molecule might be assumed to be one of important factors for the emergence of antiviral activity, because the lipophilic kanamycin A molecule could penetrate through the cell membrane infected by virus and inhibit certain stages of virus protein synthesis. Mechanism of the growth inhibition of virus is now under investigation.
Experimental
The spectrometric data were obtained by the following instruments. Melting points were determined using Yanagimoto micro melting point apparatus and are uncorrected. NMR spectra were recorded at 60 MHz on a JNM-PMX 60 NRIR spectrometer and at 100 MHz on a Jeol-MH 100 NMR spectrometer using Me,Si as an internal standard. IR spectra were taken on a Hitachi 260-10 spectrophotometer.
Optical rotations were determined with Jasco DIP-140 po!arimeter. FD-Mass spectra were measured on Jeol-D 300 mass spectromcter. Assay Assays v,ere carried out in coniatent Vero cell cultures in multi-well trays (96 wells). The cell cuitures were grown to confluence in EAGLE'S minimal essential medium (MEM) supplemented with 5°. fetal bovine serum (FBS). HSV-I Mivama and influenza virus A/PR 8 were respectively grown in Vero cells and Madin and Darby canine kidney cells (MDCK cells). The culture medium was changed to 0.5 FBS-MEM. The cell cultures were inoculated v1 ith about 100 times the virus dose needed to infect 50 percent of cells (TCID,,,) of virus, and immediately thereafter. exposed to varying concentrations of the test compound and incubated for 2 days at 37C in humidified 5"' CO,-95% air. 4 wells (multi-well trays (96 wells)) were used in each concentrations. They were fixed with 5;o trichloroacetic acid stained with 0.1 crystal violet. The viral maximal cytopathic effect (CPE) was observed microscopically (>:40). Antiviral activity was expressed as ID;,, (50 inhibitory dose), NO. 12 THE JOURNAL OF ANTIBIOTICS that is, the concentration of compound required to reduce viral CPE by 50% (within the well), when it had reached completion (100% cell destruction) in the control virus-infected cell cultures.
Cytotoxicity
In tests which were run in parallel with the antiviral assays in confluent Vero cell cultures (which had not been infected), the compounds were examined for their effects on normal cell morphology. The cytotoxicity was expressed as the minimum concentration of drug which destroyed the cell monolayer. General Procedure for Acylation of 2 1-N-Acyl-3,6'-bis(N-benzyloxycarbonyl)-3"-N-trifluoroacetylkanamycin A Derivatives (3): These derivatives (3) were obtained according to a similar manner to that of acylation of 2 described in the previous paper2) ( Table 1) .
General Procedure for Acylation of 3 To a solution of 3 (1.97 mmol) in pyridine (40 ml) was added acetic anhydride (25.6 mmol) at room temperature. The mixture was stirred at 50°C for 5 hours and allowed to stand at room temperature overnight. The reaction mixture was concentrated under reduced pressure. A solution of the residue in EtOAc (100 ml) was washed with 1 N HCI, saturated aqueous NaHCO3, and saturated aqueous NaCI successively, dried over anhydrous MgSO" and evaporated in vacuo to afford 2',3',4',2",4",6"-hexa-O-acetyl-l-N-acyl-3,6'-bis(N-benzyloxycarbonyl)-3"-N-trifluoroacetylkanamycin A derivatives (4) as a glass in good yields (Table 2) .
General Procedure for Deacetylation and Detrifluoroacetylation of 4
To a solution of potassium hydroxide (KOH) (24.9 mmol) in MeOH (50 ml) was added the derivative (4, 1.78 mmol) at room temperature and the mixture was stirred at the same temperature overnight. The reaction mixture was poured into ice-water (250 ml). The resultant precipitates were collected by filtration, washed with water, and dried to give the 1-N-acyl-3,6'-bis(N-benzyloxycarbonyl)-kanamycin A derivatives (5) in good yields (Table 3) .
General Procedure for Acylation of 5 Method A; Acylation with Acid Chloride: To a solution of 5 (32.0 mmol) in a mixture of tetrahydrofuran (THF) (600 ml) and water (150 ml) was added carboxylic acid chloride (37.4 mmol) with stirring under ice-cooling. The mixture was stirred at the same condition for 1 hour. The reaction mixture was concentrated under reduced pressure to give a suspension. The resultant precipitates were collected by filtration, washed in turn with 1 N HCI (500 ml), Et2O, iso-propyl alcohol (IPA), and water, and dried to give the 1-N-higher-acyl-3"-N-acyl-3,6'-bis(N-benzyloxycarbonyl)kanamycin A derivatives (6D' F, H, J) as a solid in good yields (Table 4) .
Method B; Acylation with Carboxylic Acid: Phosphorous oxychloride (3.16 mmol) was added to a mixture of dimethylformamide (DMF) (3.16 mmol) and THF (0.5 ml) at -10-0°C and the suspension was stirred at -5-0°C for 10 minutes. To the above suspension were added a solution of carboxylic acid (3.16 mmol) in dry THF (5 ml) at the same temperature under stirring and the mixture was stirred for 30 minutes to prepare an activated acid solution. To a solution of 5 (1.59 mmol) in a mixture of THF (40 ml) and water (10 ml) was dropwise added the activated acid solution obtained above, keeping the pH 8-9 with Et3N under ice-cooling. The reaction mixture was stirred for I hour at the same condition and concentrated under reduced pressure to give a solid. The solid was washed successively with 1 N HCI, Et.,O, and water and dried to give the 1-N-higher-acyl-3"-N-acyl-3,6'-bis(N-benzyloxycarbonyl)kanamycin A (6G, Y, a, d, e, f) as a solid in good yields (Tables 4, 5 and 6).
Method C; Acylation with N-(Acyloxy)succinimide: To a solution of 5 (1.00 mmol) in dimethyl sulfoxide (DMSO) (20 ml) were added N-(acyloxy)succinimide (2.04 mmol) and Et3N (0.3 ml) at room temperature and the mixture was stirred at the same temperature overnight. The reaction mixture was dropwise added to Et2O (200 ml). The resultant precipitates were collected by filtration, washed with Et2O and water successively, and dried to give 1-N-higher-acyl-3"-N-acyl-3,6'-bis(N-benzyloxycarbonyl)kanamycin A (61, L, M, P, Q, T, Z) as a solid in good yields. Their physical data and yields are summarized in Tables 4 and 5 .
To a solution of 5b (1.0 g) in dry THE (20 ml) was added benzyloxycarbonyl isocyanate (0.21 g) at room temperature overnight. The reaction mixture was concentrated under reduced pressure to give a solid. The solid was collected by filtration, washed with water and Et_O successively, and dried to give 6N as a solid in a good yield (Table 4) .
General Procedure for Formylation of 5 with p-Nitrophenyl Formate To a solution of 5 (0.5 mmol) in a mixture of DMF (10 ml) and water (2 ml) were added p-nitrophenyl formate (1.5 mmol) and EtN (0.08 ml) and the mixture was stirred for 2 hours. The reaction mixture was dropwise added to Et,O (200 ml). The resultant precipitates were collected by filtration, washed with Et.O, and dried to give 3,6'-bis(N-benzyloxycarbonyl)-3"-N-formyl-l-N-paI nitoyI-, or -1-N-(3-hydroxytetradecanoyl)kanamycin A (6B, V) as a solid in good yields (Tables 4 and 5 ).
3,6'-Bis(N-benzyloxycarbonyl)-1-N-palmitoyl-3"-N-phthalyikanamycin
A (6S) To a solution of 5b (0.5 g) in DMSO (10 ml) were successively added N-(ethoxycarbonyl)phthalimide (122 mg) and Et3N (0.08 ml) at room temperature. The mixture was stirred at the same temperature for 3 hours. The reaction mixture was poured into EtO (200 ml) to give a residue, which was twice washed with Et_O (200 ml). The resultant precipitates were collected by filtration and dried. The solid was subjected to column chromatography on silica gel (30 g) and eluted with a mixture of CHC1; -MeOH (10: 1). The fractions containing the desired compound were combined and concentrated under reduced pressure to give 6S (0.12 g) as a solid (Table 4) .
To a solution of 5d (800 mg) in DMF (8 ml) was added a solution of ethyl trifluoroacetate (127 mg) in DMSO (1 ml) at room temperature and the mixture was stirred at the same temperature for 2 hours. The reaction mixture was poured into ice-water (80 ml). The resultant precipitates were collected by filtration, washed successively with water (60 ml) and a mixture of IPA (20 ml) and Et,O (20 ml), and dried to give 6X as a solid (777 mg) (Table 5) .
A (6R) To a solution of 5b (0.5 g) in a mixture of THE (40 ml) and water (10 ml) was added succinic anhydride (0.06 g) and the mixture was stirred at room temperature for 3.5 hours. The reaction mixture was concentrated under reduced pressure to give a solid, which was collected by filtration, washed with water and Et,O successively, and dried to give 6R (0.55 g) as a solid (Table 4) .
3,6'-Bis(N-benzyloxycarbonyl)-I-1Y-(tert-butoxycarbonyl)kanamyc in A (10) To a solution of 2 (3 g) in a mixture of THE (48 ml) and water (12 ml) were added 2-tert-butoxycarbonyloximino-2-phenylacetonitrile (1.04 g) and Et3N (0.59 ml) at room temperature and the mixture was stirred at the same temperature for 2 hours. Furthermore, 2-tert-butoxycarbonyloximino-2-phenylacetonitrile (1.04 g) and Et3N (0.59 ml) were added to the solution and the mixture was stirred at room temperature overnight. The solution was concentrated under reduced pressure to give a crude solid (12 g).
A solution of the solid (12 g) in a mixture of DMF (50 ml) and cone NH,OH (25 ml) was stirred at room temperature overnight. Further, cone NH,OH (30 ml) was added to the solution and the mixture was stirred at room temperature for 8 hours. The reaction mixture was poured into Et2O (500 ml) and resultant precipitates were collected by filtration, washed with Et,O (100 ml) and water (100 ml) successively, and dried to give 10 (2.5 g, 82.9 %) as a solid. MP 246'-247°C; IR (Nujol) 1685, 1670 (sh), 1650, 1520, 1270 cm-1; NMR (DMSO-d,, 1) 1.36 (9H, s, (CH,),C).
Phosphorous oxychloride (0.56 ml) was added to a mixture of DMF (0.47 ml) and THE (0.9 ml) and the suspension was stirred at -5'-0°C for 10 minutes. To the above suspension was added a solution of N-(benzyloxycarbonyl)glycine (0.98 g) in THE (9 ml) at the same temperature under stirring and the solution was stirred for 30 minutes to prepare an activated acid solution. To a solution of 10 (2 g) in a mixture of THE (60 ml) and water (15 ml) was dropwise added the activated acid solution obtained above, keeping the pH 8 -9 with Et,N. The reaction mixture was stirred at the same temperature for 30 minutes and was concentrated under reduced pressure to give a suspension. The re- 8 g ) in a mixture of TFA (20 ml) and anisole (5 ml) was stirred under ice-cooling for 1 hour. The solution was concentrated under reduced pressure to give a residue, which was dissolved in a mixture of THE (60 ml) and water (15 ml). To the resultant solution was dropwise added palmitoyl chloride (0.58g) with stirring at 0-5°C, keeping the pH 8-8.5 with Et,N. The mixture was stirred under the same condition for 1 hour and the reaction mixture was concentrated under reduced pressure. The resultant solid was washed in turn with water, 1 N HCI, Et_O, and water. The solid was dried to give 6C (1.96 g, 98 %) ( Table 4) .
A (6K) To a suspension of llb (0.95 g) in anisole (2.9 ml) was added TFA (9.5 ml) under ice-cooling. The mixture was stirred at the same temperature for 2 hours and concentrated under reduced pressure to give a syrup. The syrup was dissolved in a mixture of THE (30 ml) and water (7 ml), and to the mixture was added palmitoyl chloride (265 mg) under ice-cooling, keeping the pH 8-9 with Et,N. The mixture was stirred under the same condition for 2 hours. The reaction mixture was concentrated under reduced pressure. The resultant precipitates were collected by filtration, washed with water, 1 N HCI, water, and Et,O in turn, and dried to give 6K (1.05 g, 99%) (Table 4) .
A solution of Ila (0.92 g) in a mixture of TFA (10 ml) and anisole (3 ml) was stirred under icecooling for 1 hour. The solution was concentrated under reduced pressure. To a solution of the resultant residue in a mixture of THE (40 ml) and water (10 ml) was dropwise added a solution of palmitoyl chloride (254 mg) in THE (10 ml) at 0'-5°C with stirring, keeping the pH 8 '-9 with Et,N. The mixture was stirred at the same temperature for 1 hour and the reaction mixture was concentrated under reduced pressure to give a solid. The solid was washed with I N HCI (20 ml), IPA (20 ml), Et,O (10 ml), and water in turn and dried to give 60 (0.91 g, 87%) ( Table 4) .
3"-N-Acetyl-3,6'-bis(N-benzyloxycarbonyl)-1-N-(3-hydroxytetradecanoyl)kanamycin A (6W) To a solution of 10 (2 g) in pyridine (40 ml) was added acetic anhydride (3.1 ml). The mixture was stirred at room temperature for 3 hours and allowed to stand at the same temperature overnight. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in EtOAc (100 ml) and the solution was washed with aqueous NaHCO3 and water successively, dried over anhydrous Na,SO,, and concentrated under reduced pressure to give 2',3',4',2",4",6"-hexa-O-acetyl-3"-N-acetyl-3, A solution of the compound obtained above (2.5 g) in a mixture of TFA (30 ml) and anisole (7 ml) was stirred under ice-cooling for 1 hour. The reaction mixture was concentrated in vacuo to give a crude 2',3',4',2",4",6"-hexa-O-acetyl-3"-N-acetyl-3,6'-bis(N-benzyloxycarbonyl)kanamycin A monotrifluoroacetate. Phosphorous oxychloride (0.29 ml) was added to a mixture of DMF (0.25 ml) and THE (0.5 ml) at -5 -0°C. To the resultant suspension were added successively THE (5 ml) and 3-acetoxytetradecanoic acid (706 mg) at -5 -0'C under stirring. The mixture was stirred at the same temperature for 30 minutes to prepare an activated acid solution. To a solution of the compound obtained above in a mixture of THE (40 ml) and water (10 ml) was dropwise added the activated acid solution, keeping the pH 8-9 with Et3N. The mixture was concentrated under reduced pressure. The residue was dissolved in EtOAc (120m]). The solution was washed with aqueous NaHCO3 and water in turn, dried over anhydrous Na3SO,, and concentrated under reduced pressure. The residue was subjected to column chromatography on silica gel (50 g) and eluted with a mixture of CHCI3 -MeOH (30: 1) to give 1-N-(3-acetoxytetradecanoyl)-2',3',4',2",4",6"-hexa-O-acetyl-3"-N-acetyl-3,6'-bis-(N-benzyloxycarbonyl)kanamycin A (1.95 g, 67.9%). IR (Nujol) 3270, 1720 1700, 1650, 15301510 cm-'; NMR (CDCl3, o) 0.88 (3H, br s, CH3). Furthermore, to a solution of KOH (1.16g) in MeOH (40 ml) was added the compound (1.9 g) and the mixture was stirred at room temperature for 3 hours. The resultant suspension was poured into ice-water (200 ml). The resultant precipitates were collected by filtration, washed with water, and dried to give 6W as a solid (1.20 g) (Table 5) A solution of Ila (1.0 g) in a mixture of TFA (10 ml) and anisole (3 ml) was stirred under ice-cooling for 1 hour. The solution was concentrated under reduced pressure to give a residue. To a solution of the residue (1 g) in a mixture of THE (25 ml) and water (5 ml) was dropwise added hexadecanyloxycarbonyl chloride (532 mg) with stirring under ice-cooling, keeping the pH 8-9 with Et3N. The mixture was stirred at the same temperature for 1 hour. The reaction mixture was evaporated in vacuo to give a solid. The solid was collected by filtration, washed with 1 N HCI, water, and Et,O, successively, and dried to give 6b (0.65 g, 57 %) as a solid (Table 6 ). A solution of Ila (1.9 g) in a mixture of TFA (20 ml) and anisole (6 ml) was stirred under icecooling for 1 hour. The solution was evaporated in vacuo and a solution of the residue in MeOH (20 ml) was adjusted to pH 8 -9 with aqueous solution of Na.,CO3. The mixture was poured into water (50 ml). The resultant precipitates were collected by filtration, washed with water, and dried. To a solution of the solid (1.0 g) in DMF (20 ml) was added pentadecanyl isocyanate (400 mg) at room temperature and the mixture was stirred at the same temperature overnight. Furthermore, to the mixture were added Et3N (0.2 ml) and pentadecanyl isocyanate (400 mg) and the mixture was stirred at 30-40'C for 6 hours. The reaction mixture was filtered off and the filtrate was poured into Et,O (I liter). The resultant precipitates were collected by filtration, washed with water (30 ml), and dried to give 6c (0.69 g) as a solid (Table 6 ).
General Procedure for Deprotection of 6 A solution of the derivatives (6A-Z, a-f: 1.3 mmol) in a mixture of THE (30 ml), MeOH (10 ml), and I N HCI (10 ml) was hydrogenated under atomospheric pressure of hydrogen at room temperature for 6 hours in the presence of 10% palladium on carbon (1.5 g). The catalyst was filtered off and the filtrate was evaporated in vacito to give a residue. The solution of the residue in water (40 ml) was filtered off and lyophilized to give 1-N-higher-acyl-3"-N-acylkanamycin A derivative hydrochlorides (7, 8, 9) as a hygroscopic solid. Their physical data and yields are summarized in Tables 7, 8 and 9. 
